ALK and non-small cell lung carcinoma: In the current study, we compared VENTANA IHC with the RT-PCR assay to detect ALK rearrangements and report for the first time the response and survival of crizotinib for Chinese patients with EML4-ALK positive advanced NSCLC detected by VENTANA IHC and RT-PCR.